Galapagos Awarded €1.8 Million Grant to Accelerate Drug Discovery

Galapagos NV has announced that it has been awarded a €1.8 million grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology, (IWT). 

The grant supports the development of biological models for the treatment of rheumatoid arthritis and osteoporosis, both core disease areas for Galapagos’ R&D. 

As part of this program, Galapagos will collaborate with three leading R&D institutes: the University of Antwerp, the University of Ghent and the Flanders Inter-University Institute for Biotechnology, (VIB).

The two-year program will focus on developing new biological models that will speed up the drug discovery process. 

Galapagos will work with the three institutes to develop in vitro cellular models, in vivo animal models, and ex vivo human models to evaluate the effectiveness of small molecules to treat rheumatoid arthritis and osteoporosis. 

The technology developed under the project aims to increase the success rate up to clinical Phase II Proof-of-Concept and reduce the time to get candidate drugs into the clinic.

“This €1.8 million grant from the IWT will fund a significant portion of our planned investment in new biological models,”  said Onno van de Stolpe, Chief Executive Officer of Galapagos.

“Successful development of these models would further reduce dependency on animal testing and lead to breakthrough medicines in a cost-effective and timely manner.”

“When compared to those models traditionally used by the pharmaceutical industry, the state-of-the-art technology developed in this collaboration could provide Galapagos with a cutting edge in drug discovery in bone and joint diseases.”